Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Ferrer Files Arasertaconazole IND

By Drug Discovery Trends Editor | August 9, 2012

Ferrer, a privately-held Spanish pharmaceutical company with full vertical integration from R&D to commercialisation, announces that it has filed an IND for its topical antifungal agent arasertaconazole nitrate.

The agent has recently demonstrated rapid symptomatic relief and significant clinical and mycological benefits after a single administration delivered as a vaginal suppository (pessary) formulation in a multicenter Phase 2 study in patients with vulvovaginal candidiasis (VVC). VVC, or vaginal thrush as it is also known, is a common infection affecting 70% to 75% of women at least once in their lives. The worldwide market for gynecological antifungal products exceeds $600 million per annum.

Arasertaconazole is a new, fast-acting topical antifungal. The agent has a broad spectrum of activity against Candida spp involved in VVC, including species described as resistant to fluconazole. It is the active, patented, R-enantiomer of sertaconazole nitrate, itself an antifungal agent developed by Ferrer and marketed for more than 20 years in more than 70 countries. Formulated as a vaginal suppository (pessary), arasertaconazole has demonstrated very low systemic exposure, a good safety profile and was well tolerated in clinical studies involving 283 female subjects to date.

In the multicentre Phase 2 dose-ranging study involving 229 female patients with VVC, arasertaconazole formulated as a vaginal suppository (pessary) demonstrated both fast-acting (superiority to placebo at 8 plus/minus 2 days of treatment) and prolonged (up to at least 26 plus/minus 4 days) clinical and mycological efficacy at all doses tested (150 mg, 300 mg, 600 mg). The therapeutic response to arasertaconazole was dose-dependent, with the 600 mg dose most efficacious. Moreover, arasertaconazole showed evidence of rapid relief from additional clinical symptoms (at less than 2 days, e.g. irritation and itching) when compared to placebo.  Arasertaconazole was both safe and well tolerated in this study.

“Vulvovaginal candidiasis (VVC) due to Candida infections remains a common problem worldwide, especially in women of childbearing age. The emergence of both treatment-resistant Candida species and new pathogenic strains are considered some of the reasons for the underserved medical needs in this condition,” said Antonio Guglietta, R&D Director at Ferrer. “Following discussions with the regulators, Ferrer will initiate Phase 3 clinical studies that will further differentiate arasertaconazole as a safer, fast-acting antifungal treatment for VVC in women aged more than 12 years old.”

Ferrer is currently assessing alternative formulations for arasertaconazole as treatments for other topical fungal infections that include tinea pedis (athlete’s foot).

Arasertaconazole, as well as the vaginal suppository (pessary) formulation, is the subject of granted and pending patent applications and is available for further development and commercialisation worldwide from Ferrer.

Date: August 8, 2012
Source: Ferrer


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50